

Human HER2 Sandwich ELISA Kit Datasheet

Please read it entirely before use

Catalogue Number: KE00053 Size: 96T Sensitivity: 0.02 ng/mL Range: 0.156-10 ng/mL Usage: For the quantitative detection of human HER2 concentrations in serum, plasma, cell culture supernatant and urine.

This product is for research use only and not for use in human or animal therapeutic or diagnostic.




Table of content	pa	ge
1. Background		3
2. Principle	•••••	3
3. Required Materials	•••••	3
4. Kit Components and Storage		4
5. Safety Notes		4
6. Sample Collection and Storage		4
7. Regent Preparation		5
8. Assay Procedure Summary		6
9. Validation Data		6 7
9.1 Standard curve		6 7
9.2 Precision		8
9.3 Recovery		8
9.4 Sample values		8
9.5 Sensitivity		8
9.6 Linearity		9
10. References		9

ptglab.com

1. Background

HER2, also known as ErbB2 and Neu, is a member of the epidermal growth factor (EGF) receptor family. Overexpression of HER2 have been reported in numerous cancers, including breast, ovarian, lung, gastric, and oral cancers. It is a therapeutic target for the treatment of breast cancer and other carcinomas. HER2 is a 185-kDa transmembrane glycoprotein, the extracellular domain (ECD) of which can be cleaved from the cell surface by matrix metalloproteases and then released into blood. Elevated serum HER2 levels are reported in 23% to 80% of patients with metastatic breast cancer. Raising serum HER2 levels have been correlated with indicators of poor prognosis and a poor response to chemotherapy.

2. Principle



Sandwich ELISA structure (HRP conjugated secondary antibody)

A capture antibody is pre-coated onto the bottom of wells which binds to analyte of interest. A detection antibody also binds to the analyte. Horseradish peroxidase (HRP)-conjugated secondary antibody binds to the detection antibody. TMB acts as the HRP substrate and the solution color will change from colorless to blue. A stop solution containing sulfuric acid turns solution yellow. The color intensity is proportional to the quantity of bound protein which is measurable at 450 nm with the correction wavelength set at 630 nm.

3. Required Materials

3.1 A microplate reader capable of measuring absorbance at 450 nm with the correction wavelength set at 630 nm.

3.2 Calibrated, adjustable precision pipettes and disposable plastic tips. A manifold multi-channel pipette is recommended for large assays.

3.3 Plate washer: automated or manual.

3.4 Absorbent paper towels.

3.5 Glass or plastic tubes to prepare standard and sample dilutions.

3.6 Beakers and graduated cylinders.

3.7 Log-log or semi-log graph paper or computer and software for ELISA data analysis. A four-parameter logistic (4-PL) curve-fit is recommended.

ptglab.com

4. Kit Components and Storage

Microplate - antibody coated 96-well microplate (8 well × 12 strips)	1 plate	Unopened Kit:
Protein standard - 20 ng/bottle; lyophilized	2 bottles	
Detection antibody (100×) - 120 µL/vial*	1 vial	Store at 2-8°C for 6 months or -
HRP-conjugated antibody (100×) - 120 µL/vial*	1 vial	20°C for 12 months.
Sample Diluent PT 3-ac - 30 mL/bottle. For serum and plasma samples	1 bottle	Opened Kit:
Sample Diluent PT 1-ec - 30 mL/bottle.For cell culture supernatant and urine	1 bottle	All reagents stored at 2-8°C for
Detection Diluent - 30 mL/bottle	1 bottle	7 days.
Wash Buffer Concentrate (20×) - 30 mL/bottle	1 bottle	Please use a new standard
Tetramethylbenzidine Substrate (TMB) - 12 mL/bottle	1 bottle	for each assay.
Stop Solution - 12 mL/bottle	1 bottle	ior cach assay.
Plate Cover Seals	4 pieces	

* Centrifugation immediately before use

5. Safety Notes

5.1 Avoid any skin and eye contact with Stop Solution and TMB. In case of contact, wash thoroughly with water.

5.2 Do not use the kit after the expiration date.

5.3 Do not mix or substitute reagents or materials from other kit lots or other sources.

5.4 Be sure to wear protective equipment such as gloves, masks and goggles during the experiment.

5.5 When using an automated plate washer, adding a 30 second soak period following the addition of Wash Buffer to improve assay precision

6. Sample Collection and Storage

6.1 Serum: Allow blood samples to clot for 30 minutes, followed by centrifugation for 15 minutes at 1000xg. Clear serum can be assayed immediately or aliquoted and stored at -20°C. Avoid repeated freeze-thaw cycles.

6.2 Plasma: Use EDTA, heparin, or citrate as an anticoagulant for plasma collection. Centrifuge for 15 minutes at 1000xg within 30 minutes of collection. The plasma can be assayed immediately or aliquoted and stored at -20°C. Avoid repeated freeze-thaw cycles.

6.3 Cell Culture Supernatant: Remove particulates by centrifugation for 5 minutes at 500xg and assay immediately or aliquot and store samples at \leq -20°C. Avoid repeated freeze-thaw cycles.

6.4 Urine: Collect urine samples and centrifuge for 20 minutes at 1000xg. Collect the aqueous layer, assay immediately or aliquot and store samples at \leq -20°C. Avoid repeated freeze-thaw cycles.

7. Regent Preparation

7.1 Wash Buffer (1X): If crystals have formed in the concentrate, warm to room temperature and mix gently until the crystals have completely dissolved. Add 30 mL of Wash Buffer Concentrate(20X) to 570 mL deionized or distilled water to prepare 1X Wash Buffer.

7.2 Detection Antibody (1X): Dilute 100X Detection Antibody 1:100 using Detection Diluent prior to assay. Suggested 1:100 dilution: 10 µL 100X Detection Antibody + 990 µL Detection Diluent (Centrifuge the 100 X Detection Antibody solution for a few seconds prior to use).


7.3 HRP-conjugated antibody (1X): Dilute 100X HRP-conjugated antibody 1:100 using Detection Diluent prior to assay. Suggested 1:100 dilution: 10 µL 100X HRP-conjugated antibody + 990 µL Detection Diluent (Centrifuge the 100X HRP-conjugated antibodyy solution for a few seconds prior to use).

7.4 Sample Dilution: Different samples should be diluted with corresponding Sample Diluent, samples may require further dilution if the readout values are higher than the highest standard OD reading. Variations in sample collection, processing and storage may affect the results of the measurement.

Recommended Dilution for different sample types: 1:2 or 1:4 is recommended for serum and plasma; 1:2 or 1:4 is recommended for cell culture supernatant; 1:2 or 1:4 is recommended for urine.

7.5 Standard Serial Dilution:

For human serum and plasma samples, add 2 mL Sample Diluent PT 3-ac in protein standard; For cell culture supernatant or urine samples, add 2 mL Sample Diluent PT 1-ec in protein standard.



Add # µL of Standard diluted in the previous step	-	500 μL					
# μL of Sample Diluent PT 3-ac or PT 1-ec	2000 µL	500 μL					
	"sd7"	"sd6"	"sd5"	"sd4"	"sd3"	"sd2"	"sd1"

8. Assay Procedure Summary

Bring all reagents to room temperature before use (Detection antibody and HRP-conjugated antibody can be used immediately). To avoid cross-contamination, change pipette tips between additions of each standard level, between sample additions, and between reagent additions. Also, use separate reservoirs for each reagent.

8.1 Take out the required number of microplate strips and return excess strips to the foil pouch containing the drying reagent pack and reseal; store at 4°C immediately. Microplate strips should be used in one week.

8.2 Preset the layout of the microplate, including control group, standard group and sample group, add 100 µL of each standard and sample to the appropriate wells. (Make sure sample addition is uninterrupted and completed within 5 to 10 minutes, It is recommended to assay all standards, controls, and samples in duplicate).

8.3 Seal plate with cover seal, pressing it firmly onto top of microwells. Incubate the plate for 1 hour at 37°C.8.4 Wash

1) Gently remove the cover seal. Discard the liquid from wells by aspirating or decanting. Remove any residual solution by tapping the plate a few times on fresh paper towels.

2) Wash 4 times with 1X Wash Buffer, using at least 350-400 µL per well. Following the last wash, firmly tap plates on fresh towels 10 times to remove residual Wash Buffer. Avoid getting any towel fibers in the wells or wells drying out completely.
8.5 Add 100 µL of 1X Detection Antibody solution (refer to Reagent Preparation7.2) to each well. Seal plate with cover seal and incubate for 1 hour at 37°C.

8.6 Repeat wash step in 8.4.

8.7 Add 100 μL of 1X HRP-conjugated antibody solution (refer to Reagent Preparation 7.3) to each well. Seal plate with cover seal and incubate the plate for 40 minutes at 37°C.

8.8 Repeat wash step in 8.4.

8.9 Signal development: Add 100 μL of TMB substrate solution to each well, protected from light. Incubate for 15 to 20 minutes. Substrate Solution should remain colorless until added to the plate.

8.10 Quenching color development: Add 100 µL of Stop Solution to each well in the same order as addition of the TMB substrate. Mix by tapping the side of the plate gently. NB: Avoid skin and eye contact with the Stop solution.

8.11 Read results: Immediately after adding Stop solution read the absorbance on a microplate reader at a wavelength of 450 nm. If possible, perform a double wavelength readout (450 nm and 630 nm).


8.12 Data analysis: Calculate the average of the duplicate readings (OD value) for each standard and sample, and subtract the average of the zero standard absorbance. Construct a standard curve by plotting the mean absorbance for each standard on the y-axis against the concentration on the x-axis, use four-parameter logistic curve- fit (4-PL) analysis to do this. If the samples have been diluted, the OD readout from the standard curve must be multiplied by the dilution factor used.

Step	Reagent	Volume	Incubation	Wash	Notes		
1	Standard and Samples	100 µL	60 min	4 times	Cover Wells incubate at 37°C		
2	Diluent Antibody Solution	100 µL	60 min	4 times	Cover Wells incubate at 37°C		
3	Diluent HRP Solution	100 µL	40 min	4 times	Cover Wells incubate at 37°C		
4	TMB Substrate	100 µL	15-20 min	Do not wash	Incubate in the dark at 37°C		
5	Stop Solution	100 µL	0 min	Do not wash	-		
6	6 Read plate at 450 nm and 630 nm immediately after adding Stop solution. DO NOT exceed 5 minutes.						


9. Validation Data

9.1 Standard curve

These standard curves are provided for demonstration only. A standard curve should be generated for each set of samples assayed.



(ng/mL)	0.D	Average	Corrected
0	0.045 0.045	0.045	-
0.125	0.098 0.101	0.0995	0.0545
0.313	0.154 0.152	0.153	0.108
0.625	0.263 0.25	0.2565	0.2115
1.25	0.443 0.447	0.445	0.4
2.5	0.793 0.763	0.778	0.733
5	1.323 1.307	1.315	1.27
10	2.084 2.099	2.0915	2.0465



(ng/mL)	0.D	Average	Corrected
0	0.037 0.036	0.0365	-
0.156	0.083 0.084	0.0835	0.047
0.313	0.137 0.136	0.1365	0.1
0.625	0.229 0.232	0.2305	0.194
1.25	0.427 0.412	0.4195	0.383
2.5	0.668 0.655	0.6615	0.625
5	1.238 1.222	1.23	1.1935
10	1.912 1.958	1.935	1.8985

ptglab.com

9.2 Precision

Intra-assay Precision (Precision within an assay) Three samples of known concentration were tested 20 times on one plate to assess intra-assay precision.

Inter-assay Precision (Precision between assays) Three samples of known concentration were tested in 24 separate assays to assess inter-assay precision.

Intra-assay Precision					Inter-assay Precision					
Sample	n	Mean (ng/mL)	SD	CV%		Sample	n	Mean (ng/mL)	SD	CV%
1	20	7.74	0.307	3.97		1	24	6.81	0.365	5.37
2	20	1.53	0.054	3.55		2	24	1.42	0.068	4.81
3	20	0.41	0.014	3.43		3	24	0.35	0.021	5.86

9.3 Recovery

The recovery of human HER2 spiked to three different levels throughout the range of the assay in various matrices was evaluated.

Sample Type		Average% of Expected	Range (%)
	1:2	99	91-105
Human plasma	1:4	96	83-106
	1:2	98	92-106
Cell culture supernatant	1:4	100	93-108
Urine	1:2	101	91-121
	1:4	102	92-118

9.4 Sample values

Twenty-eight serum samples from volunteers were evaluated for human HER2 in this assay. No medical histories were available for the donors used in this study.

Sample Type	The Detection Rate	Mean of Detectable (ng/mL)	Range (ng/mL)
Serum (n=28)	37%	1.43	0.12-9.12

9.5 Sensitivity

The minimum detectable dose of human HER2 is 0.02 ng/mL. This was determined by adding two standard deviations to the concentration corresponding to the mean O.D. of 20 zero standard replicates.

9.6 Linearity

To assess the linearity of the assay, three samples were spiked with high concentrations of human HER2 in various matrices and diluted with the appropriate **Sample Diluent** to produce samples with values within the dynamic range of the assay.

		Human plasma (Sample Diluent PT 3-ac)	Cell culture supernatant (Sample Diluent PT 1-ec)	Urine (Sample Diluent PT 1-ec)
1:2	Average% of Expected	108	93	107
1.2	Range (%)	98-118	90-97	102-114
1./	Average% of Expected	101	99	102
1:4	Range (%)	99-103	96-102	96-114
1:8	Average% of Expected	99	101	101
1.0	Range (%)	96-102	97-103	93-112
1:16	Average% of Expected	102	101	104
1.10	Range (%)	98-106	98-107	91-119

10. References

1. Hung MC, et al. Basic science of HER-2/neu: a review. Semin Oncol. 26(4 Suppl 12):51-9 (1999).

2. Slamon DJ, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 344(11):783-92 (2001).

3. Pupa SM, et al. The extracellular domain of the c-erbB-2 oncoprotein is released from tumor cells by proteolytic cleavage. Oncogene. 8(11):2917-23 (1993).

4. Carney WP, et al. Potential clinical utility of serum HER-2/neu oncoprotein concentrations in patients with breast cancer. Clin Chem. 49(10):1579-98 (2003).

5. Colomer R, et al. Circulating HER2 extracellular domain and resistance to chemotherapy in advanced breast cancer. Clin Cancer Res. 6(6):2356-62 (2000).

